Debate: Optimal approach for the management of CLL patients with del(17p) – Novel Agents

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul Barr argues that the optimal treatment for chronic lymphocytic leukemia (CLL) patients with a 17p deletion is the use of a novel agent.

A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204

© 2016 Imedex, LLC.